On 23 December 2020, Voronezh State University, Moscow State University, and the State Research Centre of Virology and Biotechnology Vector of Rospotrebnadzor (Novosibirsk) signed a trilateral agreement on the joint research for the design of effective direct-acting drugs for the coronavirus SARS-CoV-2. The joint research will be comprehensive and aimed at the development of anti-viral drugs acting against coronaviruses, including SARS-CoV-2.
A research group from Moscow State University is docking the combinatorial libraries of heterocyclic compounds in order to obtain data on the virtual activity of various substances against the target protein, the main protease of coronavirus. A research group from Voronezh State University led by Professor Khidmet Shikhaliyev, the Head of the VSU Department of Organic Chemistry, is working on the molecular design and the development of the methods of synthesis of the leading compounds. The researchers at Vector of Rospotrebnadzor are studying the anti-viral activity of the synthesised substances. A series of substances that are highly active against the coronavirus SARS-CoV-2 and outperform foreign analogues has already been found among the studied compounds.
The obtained results can become a scientific foundation for creating next-generation anti-viral drugs which would be effective for the treatment of infectious diseases, including the new coronavirus. Several joint trilateral applications for international patents for the new anti-viral drugs are being prepared.
“The signed agreement is a guarantee of the successful cooperation between the leading universities and one of the largest research centres of virology and biotechnology in Russia. A science and technology consortium has been formed, and the coordinated activities of all its members is aimed at the solution of the most relevant task of our time, the search for a drug that will effectively fight the new coronavirus”, noted Oleg Kozaderov, Vice Rector for Research and Innovations at VSU.